Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial
Eugenio Mercuri, Nicolas Deconinck, Elena Mazzone, et al.
The Lancet Neurology (2021) Vol. 21, Iss. 1, pp. 42-52
Closed Access | Times Cited: 150

Showing 1-25 of 150 citing articles:

Spinal muscular atrophy
Eugenio Mercuri, Charlotte J. Sumner, Francesco Muntoni, et al.
Nature Reviews Disease Primers (2022) Vol. 8, Iss. 1
Closed Access | Times Cited: 234
Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data
Judit Erdös, Claudia Wild
European Journal of Paediatric Neurology (2022) Vol. 39, pp. 1-10
Open Access | Times Cited: 75
Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment
Hisahide Nishio, Emma Tabe Eko Niba, Toshio Saito, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 11939-11939
Open Access | Times Cited: 62
Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)
Maryam Oskoui, John Day, Nicolas Deconinck, et al.
Journal of Neurology (2023) Vol. 270, Iss. 5, pp. 2531-2546
Open Access | Times Cited: 59
Assessing disease progression in Spinal Muscular Atrophy, current gaps, and opportunities: a narrative review
Robert Muni‐Lofra, Giorgia Coratti, Tina Duong, et al.
Neuromuscular Disorders (2025), pp. 105341-105341
Open Access | Times Cited: 2
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo‐controlled, dose‐finding trial followed by 24 months of treatment
Eugenio Mercuri, Giovanni Baranello, Odile Boespflug‐Tanguy, et al.
European Journal of Neurology (2022) Vol. 30, Iss. 7, pp. 1945-1956
Open Access | Times Cited: 51
Curing SMA: Are we there yet?
Aoife Reilly, Lucia Chehadé, Rashmi Kothary
Gene Therapy (2022) Vol. 30, Iss. 1-2, pp. 8-17
Open Access | Times Cited: 43
Risdiplam: A Review in Spinal Muscular Atrophy
Julia Paik
CNS Drugs (2022) Vol. 36, Iss. 4, pp. 401-410
Open Access | Times Cited: 41
Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study
Claudia A. Chiriboga, Claudio Bruno, Tina Duong, et al.
Neurology and Therapy (2023) Vol. 12, Iss. 2, pp. 543-557
Open Access | Times Cited: 39
Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study
Georg M. Stettner, Oswald Hasselmann, Anne Tscherter, et al.
BMC Neurology (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 33
New therapies for spinal muscular atrophy: where we stand and what is next
Laura Antonaci, Maria Carmela Pera, Eugenio Mercuri
European Journal of Pediatrics (2023) Vol. 182, Iss. 7, pp. 2935-2942
Open Access | Times Cited: 27
Risdiplam in non‐sitter patients aged 16 years and older with 5q spinal muscular atrophy
Nancy Carolina Ñungo Garzón, Inmaculada Pitarch Castellano, Teresa Sevilla, et al.
Muscle & Nerve (2023) Vol. 67, Iss. 5, pp. 407-411
Open Access | Times Cited: 24
Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England
Diana Weidlich, Laurent Servais, Imran Kausar, et al.
Neurology and Therapy (2023) Vol. 12, Iss. 4, pp. 1205-1220
Open Access | Times Cited: 24
2024 update: European consensus statement on gene therapy for spinal muscular atrophy
Janbernd Kirschner, G. Bernert, Nina Butoianu, et al.
European Journal of Paediatric Neurology (2024) Vol. 51, pp. 73-78
Open Access | Times Cited: 12
Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy
Edmar Zanoteli, Alexandra Prufer de Queiroz Campos Araújo, Michele Michelin Becker, et al.
Arquivos de Neuro-Psiquiatria (2024) Vol. 82, Iss. 01, pp. 001-018
Open Access | Times Cited: 10
An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies
Doris Giess, Judit Erdos, Claudia Wild
European Journal of Paediatric Neurology (2024) Vol. 51, pp. 84-92
Closed Access | Times Cited: 10
Functional class criteria identification in patients with spinal muscular atrophy 5q
Yu. О. Papina, Е. А. Melnik, Е. Д. Белоусова, et al.
Neuromuscular Diseases (2025) Vol. 14, Iss. 4, pp. 58-70
Open Access | Times Cited: 1
Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence
Helgi Thor Hjartarson, Kristofer Nathorst-Böös, Thomas Sejersen
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 1865-1883
Open Access | Times Cited: 38
Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA)
Theodora Markati, Gemma Fisher, Sithara Ramdas, et al.
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 5, pp. 451-461
Open Access | Times Cited: 29
The 2022 yearbook of Neurorestoratology
Hongyun Huang, John R. Bach, Hari Shanker Sharma, et al.
Journal of Neurorestoratology (2023) Vol. 11, Iss. 2, pp. 100054-100054
Open Access | Times Cited: 21
Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6–48 months with Duchenne muscular dystrophy amenable to exon 51 skipping
Eugenio Mercuri, A. Seferian, Laurent Servais, et al.
Neuromuscular Disorders (2023) Vol. 33, Iss. 6, pp. 476-483
Closed Access | Times Cited: 19
Respiratory morbidity in patients with spinal muscular atrophy—a changing world in the light of disease-modifying therapies
Leen Lagae, Marijke Proesmans, M. van den Hauwe, et al.
Frontiers in Pediatrics (2024) Vol. 12
Open Access | Times Cited: 8
Risdiplam in Spinal Muscular Atrophy: Safety Profile and Use Through The Early Access to Medicine Scheme for the Paediatric Cohort in Great Britain
Nikki Cornell, Anne‐Marie Childs, Elizabeth Wraige, et al.
Journal of Neuromuscular Diseases (2024) Vol. 11, Iss. 2, pp. 361-368
Open Access | Times Cited: 7
A Systematic Literature Review of the Natural History of Respiratory, Swallowing, Feeding, and Speech Functions in Spinal Muscular Atrophy (SMA)
Yasmina Martí, Valerie Aponte Ribero, Sarah Batson, et al.
Journal of Neuromuscular Diseases (2024) Vol. 11, Iss. 5, pp. 889-904
Open Access | Times Cited: 7
An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy
Jennifer M. Kwon, Kapil Arya, Nancy L. Kuntz, et al.
Annals of Clinical and Translational Neurology (2022) Vol. 9, Iss. 6, pp. 810-818
Open Access | Times Cited: 27
Page 1 - Next Page

Scroll to top